DMDanelia Mendieta-Cabrera

Danelia Mendieta-Cabrera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Danelia Mendieta-Cabrera has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Use of Extracellular Monomeric Ubiquitin as a Therapeutic Option for Major Depressive Disorder

    by José Luis Maldonado-García, Lissette Haydee García-Mena, Danelia Mendieta-Cabrera, Gilberto Pérez-Sánchez, Enrique Becerril-Villanueva, Samantha Alvarez-Herrera, Toni Homberg, Luis Vallejo-Castillo, Sonia Mayra Pérez-Tapia, Martha C. Moreno-Lafont, et al.

    Major depressive disorder (MDD) is a mood disorder that has become a global health emergency according to the World Health Organization (WHO). It affects 280 million people worldwide and is a leading cause of disability and financial loss. Patients with MDD present immunoendocrine alterations like cortisol resistance and inflammation, which are associated with alterations in neurotransmitter metabolism. There are currently numerous therapeutic options for patients with MDD; however, some studies suggest a high rate of therapeutic failure. There are multiple hypotheses explaining the pathophysiological mechanisms of MDD, in which several systems are involved, including the neuroendocrine and immune systems. In recent years, inflammation has become an important target for the development of new therapeutic options. Extracellular monomeric ubiquitin (emUb) is a molecule that has been shown to have immunomodulatory properties through several mechanisms including cholinergic modulation and the generation of regulatory T cells. In this perspective article, we highlight the influence of the inflammatory response in MDD. In addition, we review and discuss the evidence for the use of emUb contained in Transferon as a concomitant treatment with selective serotonin reuptake inhibitors (SSRIs).


  • IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients

    by Danelia Mendieta, Dora Luz De la Cruz-Aguilera, Maria Isabel Barrera-Villalpando, Enrique Becerril-Villanueva, Rodrigo Arreola, Erick Hernández-Ferreira, Sonia Mayra Pérez-Tapia, Gilberto Pérez-Sánchez, María Eugenia Garcés-Alvarez, Lucinda Aguirre-Cruz, et al.